SHL Telemedicine Ltd. Logo

SHL Telemedicine Ltd.

SHLT

(1.0)
Stock Price

2,75 USD

-11.76% ROA

-9.44% ROE

-4.88x PER

Market Cap.

46.059.913,00 USD

20.46% DER

0% Yield

-12.39% NPM

SHL Telemedicine Ltd. Stock Analysis

SHL Telemedicine Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

SHL Telemedicine Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (48%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.23x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (54.276), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

4 ROE

The stock's ROE indicates a negative return (-0.14%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-0.13%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

SHL Telemedicine Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

SHL Telemedicine Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

SHL Telemedicine Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

SHL Telemedicine Ltd. Revenue
Year Revenue Growth
2002 89.804.000
2003 98.784.000 9.09%
2004 103.052.000 4.14%
2005 99.048.000 -4.04%
2006 62.848.000 -57.6%
2007 62.124.000 -1.17%
2008 44.554.000 -39.44%
2009 47.890.000 6.97%
2010 50.252.000 4.7%
2011 42.374.000 -18.59%
2012 26.938.000 -57.3%
2013 29.674.000 9.22%
2014 39.976.000 25.77%
2015 46.276.000 13.61%
2015 34.581.000 -33.82%
2016 40.548.000 14.72%
2017 37.378.000 -8.48%
2018 48.863.000 23.5%
2019 41.884.000 -16.66%
2020 40.164.000 -4.28%
2021 49.582.000 18.99%
2022 58.998.000 15.96%
2023 56.140.000 -5.09%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

SHL Telemedicine Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2002 415.000
2003 672.000 38.24%
2004 712.000 5.62%
2005 915.000 22.19%
2006 911.000 -0.44%
2007 2.550.000 64.27%
2008 1.003.000 -154.24%
2009 1.223.000 17.99%
2010 1.597.000 23.42%
2011 1.334.000 -19.72%
2012 -1.475.000 190.44%
2013 -1.599.000 7.75%
2014 -1.311.000 -21.97%
2015 2.060.000 163.64%
2015 -1.002.000 305.59%
2016 -1.113.000 9.97%
2017 -981.000 -13.46%
2018 173.000 667.05%
2019 2.511.000 93.11%
2020 -360.000 797.5%
2021 -431.000 16.47%
2022 3.788.000 111.38%
2023 5.742.000 34.03%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

SHL Telemedicine Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 26.676.000
2003 32.722.000 18.48%
2004 32.835.000 0.34%
2005 33.965.000 3.33%
2006 9.668.000 -251.31%
2007 14.924.000 35.22%
2008 11.527.000 -29.47%
2009 10.142.000 -13.66%
2010 10.945.000 7.34%
2011 11.910.000 8.1%
2012 3.469.000 -243.33%
2013 2.991.000 -15.98%
2014 3.002.000 0.37%
2015 10.932.000 72.54%
2015 3.467.000 -215.32%
2016 4.751.000 27.03%
2017 2.541.000 -86.97%
2018 2.652.000 4.19%
2019 2.834.000 6.42%
2020 3.930.000 27.89%
2021 3.950.000 0.51%
2022 20.829.000 81.04%
2023 15.078.000 -38.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

SHL Telemedicine Ltd. EBITDA
Year EBITDA Growth
2002 11.655.000
2003 3.070.000 -279.64%
2004 -1.708.000 279.74%
2005 469.000 464.18%
2006 9.702.000 95.17%
2007 45.622.000 78.73%
2008 11.378.000 -300.97%
2009 12.949.000 12.13%
2010 12.698.000 -1.98%
2011 13.550.000 6.29%
2012 -628.000 2257.64%
2013 -470.000 -33.62%
2014 8.157.000 105.76%
2015 5.692.000 -43.31%
2015 -5.773.000 198.6%
2016 4.944.000 216.77%
2017 8.871.000 44.27%
2018 16.398.000 45.9%
2019 9.236.000 -77.54%
2020 5.302.000 -74.2%
2021 -7.326.000 172.37%
2022 2.136.000 442.98%
2023 -4.273.000 149.99%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

SHL Telemedicine Ltd. Gross Profit
Year Gross Profit Growth
2002 45.751.000
2003 46.659.000 1.95%
2004 44.650.000 -4.5%
2005 44.647.000 -0.01%
2006 32.704.000 -36.52%
2007 32.550.000 -0.47%
2008 31.763.000 -2.48%
2009 34.369.000 7.58%
2010 35.560.000 3.35%
2011 26.982.000 -31.79%
2012 14.305.000 -88.62%
2013 15.940.000 10.26%
2014 22.264.000 28.4%
2015 22.480.000 0.96%
2015 14.023.000 -60.31%
2016 21.069.000 33.44%
2017 19.593.000 -7.53%
2018 30.214.000 35.15%
2019 23.462.000 -28.78%
2020 20.644.000 -13.65%
2021 24.593.000 16.06%
2022 27.189.000 9.55%
2023 24.968.000 -8.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

SHL Telemedicine Ltd. Net Profit
Year Net Profit Growth
2002 1.411.000
2003 -10.195.000 113.84%
2004 -4.717.000 -116.13%
2005 -7.548.000 37.51%
2006 -8.464.000 10.82%
2007 23.375.000 136.21%
2008 2.233.000 -946.8%
2009 5.377.000 58.47%
2010 4.861.000 -10.62%
2011 3.997.000 -21.62%
2012 -7.304.000 154.72%
2013 2.232.000 427.24%
2014 829.000 -169.24%
2015 -4.992.000 116.61%
2015 -16.635.000 69.99%
2016 -11.096.000 -49.92%
2017 2.408.000 560.8%
2018 10.141.000 76.25%
2019 5.695.000 -78.07%
2020 278.000 -1948.56%
2021 -14.110.000 101.97%
2022 -76.000 -18465.79%
2023 -9.678.000 99.21%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

SHL Telemedicine Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 -1 0%
2004 0 0%
2005 -1 0%
2006 -1 0%
2007 2 100%
2008 0 0%
2009 1 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 0 0%
2015 -2 100%
2016 -1 0%
2017 0 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 -1 100%
2022 0 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

SHL Telemedicine Ltd. Free Cashflow
Year Free Cashflow Growth
2002 -2.383.000
2003 -4.894.000 51.31%
2004 -4.968.000 1.49%
2005 -7.090.000 29.93%
2006 -4.536.000 -56.31%
2007 -7.678.000 40.92%
2008 -12.799.000 40.01%
2009 -1.698.000 -653.77%
2010 -2.701.000 37.13%
2011 -8.086.000 66.6%
2012 -2.806.000 -188.17%
2013 -1.263.000 -122.17%
2014 -7.396.000 82.92%
2015 1.230.000 701.3%
2015 3.936.000 68.75%
2016 -2.243.000 275.48%
2017 10.242.000 121.9%
2018 11.509.000 11.01%
2019 8.876.000 -29.66%
2020 2.910.000 -205.02%
2021 -3.073.000 194.7%
2022 -6.977.000 55.96%
2023 543.000 1384.9%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

SHL Telemedicine Ltd. Operating Cashflow
Year Operating Cashflow Growth
2002 2.215.000
2003 645.000 -243.41%
2004 1.305.000 50.57%
2005 -208.000 727.4%
2006 1.800.000 111.56%
2007 -1.801.000 199.94%
2008 -7.550.000 76.15%
2009 5.260.000 243.54%
2010 3.008.000 -74.87%
2011 -3.503.000 185.87%
2012 1.626.000 315.44%
2013 2.815.000 42.24%
2014 -3.117.000 190.31%
2015 3.980.000 178.32%
2015 5.036.000 20.97%
2016 -429.000 1273.89%
2017 11.844.000 103.62%
2018 12.756.000 7.15%
2019 10.850.000 -17.57%
2020 4.682.000 -131.74%
2021 185.000 -2430.81%
2022 -73.000 353.42%
2023 898.500 108.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

SHL Telemedicine Ltd. Capital Expenditure
Year Capital Expenditure Growth
2002 4.598.000
2003 5.539.000 16.99%
2004 6.273.000 11.7%
2005 6.882.000 8.85%
2006 6.336.000 -8.62%
2007 5.877.000 -7.81%
2008 5.249.000 -11.96%
2009 6.958.000 24.56%
2010 5.709.000 -21.88%
2011 4.583.000 -24.57%
2012 4.432.000 -3.41%
2013 4.078.000 -8.68%
2014 4.279.000 4.7%
2015 2.750.000 -55.6%
2015 1.100.000 -150%
2016 1.814.000 39.36%
2017 1.602.000 -13.23%
2018 1.247.000 -28.47%
2019 1.974.000 36.83%
2020 1.772.000 -11.4%
2021 3.258.000 45.61%
2022 6.904.000 52.81%
2023 355.500 -1842.05%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

SHL Telemedicine Ltd. Equity
Year Equity Growth
2002 90.459.000
2003 86.130.000 -5.03%
2004 81.515.000 -5.66%
2005 40.783.000 -99.87%
2006 29.806.000 -36.83%
2007 60.496.000 50.73%
2008 59.073.000 -2.41%
2009 65.301.000 9.54%
2010 74.696.000 12.58%
2011 66.563.000 -12.22%
2012 60.986.000 -9.14%
2013 68.910.000 11.5%
2014 61.396.000 -12.24%
2015 42.597.000 -44.13%
2016 23.815.000 -78.87%
2017 29.209.000 18.47%
2018 37.684.000 22.49%
2019 34.743.000 -8.47%
2020 37.878.000 8.28%
2021 60.763.000 37.66%
2022 59.289.000 -2.49%
2023 76.461.453 22.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

SHL Telemedicine Ltd. Assets
Year Assets Growth
2002 207.892.000
2003 196.427.000 -5.84%
2004 195.743.000 -0.35%
2005 137.376.000 -42.49%
2006 128.319.000 -7.06%
2007 144.163.000 10.99%
2008 81.825.000 -76.18%
2009 86.573.000 5.48%
2010 95.064.000 8.93%
2011 108.196.000 12.14%
2012 99.735.000 -8.48%
2013 108.515.000 8.09%
2014 92.127.000 -17.79%
2015 74.454.000 -23.74%
2016 62.629.000 -18.88%
2017 65.503.000 4.39%
2018 55.527.000 -17.97%
2019 59.800.000 7.15%
2020 64.814.000 7.74%
2021 129.592.000 49.99%
2022 110.783.000 -16.98%
2023 113.049.671 2.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

SHL Telemedicine Ltd. Liabilities
Year Liabilities Growth
2002 115.832.000
2003 108.870.000 -6.39%
2004 114.228.000 4.69%
2005 96.593.000 -18.26%
2006 98.513.000 1.95%
2007 83.667.000 -17.74%
2008 22.752.000 -267.73%
2009 21.272.000 -6.96%
2010 20.368.000 -4.44%
2011 41.633.000 51.08%
2012 38.749.000 -7.44%
2013 39.605.000 2.16%
2014 30.731.000 -28.88%
2015 31.857.000 3.53%
2016 38.814.000 17.92%
2017 36.294.000 -6.94%
2018 17.843.000 -103.41%
2019 25.057.000 28.79%
2020 26.936.000 6.98%
2021 68.829.000 60.87%
2022 51.494.000 -33.66%
2023 36.588.217 -40.74%

SHL Telemedicine Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.65
Net Income per Share
-0.58
Price to Earning Ratio
-4.88x
Price To Sales Ratio
0.81x
POCF Ratio
-23.46
PFCF Ratio
-9.36
Price to Book Ratio
0.47
EV to Sales
1.04
EV Over EBITDA
-27.5
EV to Operating CashFlow
-40.48
EV to FreeCashFlow
-12.04
Earnings Yield
-0.2
FreeCashFlow Yield
-0.11
Market Cap
0,05 Bil.
Enterprise Value
0,06 Bil.
Graham Number
8.83
Graham NetNet
-0.11

Income Statement Metrics

Net Income per Share
-0.58
Income Quality
0.21
ROE
-0.09
Return On Assets
-0.06
Return On Capital Employed
-0.08
Net Income per EBT
1.18
EBT Per Ebit
0.83
Ebit per Revenue
-0.13
Effective Tax Rate
-0.15

Margins

Sales, General, & Administrative to Revenue
0.21
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.44
Operating Profit Margin
-0.13
Pretax Profit Margin
-0.1
Net Profit Margin
-0.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.12
Free CashFlow per Share
-0.4
Capex to Operating CashFlow
-2.36
Capex to Revenue
0.06
Capex to Depreciation
0.71
Return on Invested Capital
-0.09
Return on Tangible Assets
-0.12
Days Sales Outstanding
60.87
Days Payables Outstanding
44.79
Days of Inventory on Hand
43.67
Receivables Turnover
6
Payables Turnover
8.15
Inventory Turnover
8.36
Capex per Share
0.28

Balance Sheet

Cash per Share
2,15
Book Value per Share
6,26
Tangible Book Value per Share
1.9
Shareholders Equity per Share
6.02
Interest Debt per Share
1.35
Debt to Equity
0.2
Debt to Assets
0.13
Net Debt to EBITDA
-6.11
Current Ratio
2.3
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
87948205
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.47
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
3623011
Debt to Market Cap
0.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

SHL Telemedicine Ltd. Dividends
Year Dividends Growth

SHL Telemedicine Ltd. Profile

About SHL Telemedicine Ltd.

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.

CEO
Mr. David Arnon
Employee
583
Address
Ashdar Building
Tel Aviv, 67891

SHL Telemedicine Ltd. Executives & BODs

SHL Telemedicine Ltd. Executives & BODs
# Name Age
1 Mr. David Arnon
Chief Executive Officer
70
2 Mr. Bernd Altpeter
Managing Director of SHL Telemedizin Germany
70
3 Mr. Amir Hai
Chief Financial Officer
70

SHL Telemedicine Ltd. Competitors